Released on: October 17, 2008, 9:42 pm

Press Release Author: Sahajanand Medical Technologies

Industry: Healthcare

Press Release Summary: Sirolimus Eluting Stent for leading drug eluting stets
developer & manufacturer Sahajanand Medical Technologies Pvt. Ltd. (SMT) displayed
positive results in MAXIMUS trial that included 100 patients from the Max Heart
institute in India.

Press Release Body: WASHIGTON DC Oct.12, 2008 - Sahajanand Medical Technologies Pvt.
Ltd. (SMT), Surat, India, leading developer and manufacturer of drug-eluting stents,
welcomed the positive results achieved by Supralimus Core™ (Sirolimus Eluting Stents
on unique chromium cobalt platform with a biodegradable Polymer) in the MAXIMUS
trial.

MAXIMUS trial was designed to assess the safety and efficacy of the Supralimus-Core™
(Sirolimus Eluting Stent) in de novo native obstructive coronary artery disease. It
included 100 patients from the prestigious Max Heart institute in India.

The study population was reflective of EURreal worldEUR patients with smaller vessels,
high incidence of diabetes (36%) and other cardiovascular risk factors.

The 8-months angiographic results, analyzed by Cardialysis (Rotterdam, Netherlands)
showed extremely low TLR (Target Lesion Revascularization) at (1%) Stent Thrombosis
(2%) at 1 year and low angiographic in-segment restenosis rates (4.6%) at 8 months.
The results compare favorably to other drug eluting stents current in clinically
practice.

The 12 month results of MAXIMUS, which were unveiled by Dr. Ashok Seth (Chairman and
Chief cardiologist, Escorts Heart Institute, New Delhi, India) on Monday, October
12th at the Transcatheter Cardiovascular Therapeutics (TCT) conference in
Washington, DC.
EURThe results of Supralimus Core in a real world population with high incidence of
diabetes and relatively smaller vessels are extremely promising. It also has the
additional advantage of biodegradable polymer which disappears over a period of time
then alleviating some of the concern related to persistent polymer
hypersensitivity.EUR Dr Seth commented.

Dr Atul Abhyankar, Medical Director- Sahajanand's Medical Technologies, shared the
enthusiasm "The results of TLR and MACE are very low, especially the low stent
thrombosis rates at one year are very impressive and encourage us to further
document these results in larger comparative trials.EUR

Mr. Dhirajlal Kotadia, the Founder and Chairman of SMT; shared the importance of the
company's commitment to continuously trying to address unmet medical needs and
provide patients and clinicians with choice. We will continue our investment in
clinical research and ensure the delivery of evidence-based treatments to all
deserving patients around the world.EUR he added.

Web Site: http://www.smtpl.com

Contact Details: JP Dutta
Chief Operating Officer
dutta@sahmed.com
Sahajanand Medical Technologies Pvt. Ltd.
Sahajanand House, Parsi Street,
Saiyedpura. Surat - 395 003, India.
stent@sahmed.com
+91-261-245-1451